General Information of Drug (ID: DMDGPKS)

Drug Name
RG7625 Drug Info
Synonyms
Petesicatib; UNII-A26QO95U37; A26QO95U37; RG-7625; RO-5459072; Petesicatib [INN]; SCHEMBL700776; GTPL9855; KXAAIORSMACJSI-AEFFLSMTSA-N; RO5459072; 2-Pyrrolidinecarboxamide, N-(1-cyanocyclopropyl)-4-((4-(1-methyl-1H-pyrazol-4-yl)-2-(trifluoromethyl)phenyl)sulfonyl)-1-((1-(trifluoromethyl)cyclopropyl)carbonyl)-, (2S,4R)-; 1252637-35-6; (2S,4R)-N-(1-cyanocyclopropyl)-4-[4-(1-methylpyrazol-4-yl)-2-(trifluoromethyl)phenyl]sulfonyl-1-[1-(trifluoromethyl)cyclopropanecarbonyl]pyrrolidine-2-carboxamide; (2s,4r)-4-[4-(1-me
Indication
Disease Entry ICD 11 Status REF
Autoimmune disease 4A40-4A45 Phase 2 [1]
Sjogren syndrome 4A43.20 Phase 2 [1]
Coeliac disease DA95 Phase 1 [1]
Cross-matching ID
PubChem CID
59543597
CAS Number
CAS 1252637-35-6
TTD Drug ID
DMDGPKS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug(s) Targeting Cathepsin S (CTSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [2]
VBY- 891 DMTKPH4 Autoimmune diabetes 5A10 Phase 1 [3]
VBY- 036 DMULRYC Neuropathic pain 8E43.0 Phase 1 [4]
VBY-129 DM4YIWK Autoimmune diabetes 5A10 Phase 1 [5]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [6]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [6]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [6]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [7]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [6]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin S (CTSS) TTUMQVO CATS_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
4 Clinical pipeline report, company report or official report of ViroBay.
5 Clinical pipeline report, company report or official report of ViroBay.
6 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
7 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.